EP1017694A2 - N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives - Google Patents
N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivativesInfo
- Publication number
- EP1017694A2 EP1017694A2 EP98951421A EP98951421A EP1017694A2 EP 1017694 A2 EP1017694 A2 EP 1017694A2 EP 98951421 A EP98951421 A EP 98951421A EP 98951421 A EP98951421 A EP 98951421A EP 1017694 A2 EP1017694 A2 EP 1017694A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- disorders
- alkyl
- formula
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- This invention relates to novel compounds, to processes for preparing them, and to their use as therapeutic agents.
- EP-A- 0556008 discloses condensed imidazopyridine derivatives with psychotropic activity, including the compound l,6-naphthyridine-6(5H)-carboxylic acid, 4- azido-3-[[(l,l-dimethylethoxy) carbonyl] amino]-7,8-dihydro, ethyl ester.
- WO96/39382 discloses the preparation of N-heterocycyl-ureas as 5-HT antagonists, including the compound N-(l -methyl- lH-indol-5-yl)-N'-( 1,2,3 ,4-tetrahydro-7- isoquinolinyl)-urea.
- naphthyridinyl-urea compounds of formula (I) below possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
- Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
- MS multiple sclerosis
- ALS amyotrophic lateral sclerosis
- the present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof:
- the compounds of this invention are typically N-(tetrahydronaphthyridinyl), N' -optionally substituted phenyl-ureas or thioureas. Especially the compounds of the invention are (tetrahydronaphthyridin-3-yl) ureas or thioureas.
- the phenyl moiety may be substituted by up to three, preferably 2 or 1, groups.
- alkyl groups including alkyl groups that are part of another moiety, may be straight chain or branched.
- .Aromatic rings such as the aromatic ring in the bicyclic heterocyclic moiety in formula (I) and phenyl groups, including phenyl groups that are part of other moieties, in R may optionally be substituted with one or more independently selected substituents such as halogen or C j . ⁇ alkyl, C ⁇ g alkoxy or C g alkylcarbonyl groups, or other optional subtituents indicated below.
- Suitable C ⁇ cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- Suitable halo substituents include fluoro, chloro, iodo and bromo, which may also appear in haloalkyl, haloalkyloxy and haloalkyl carbonyl groups mentioned above, examples of which are trifluoromethyl, trifluoromethoxy and trifiuoroacetyl.
- R represents heterocyclyl
- this group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated or unsaturated, for example containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen or sulphur, for example oxazolyl, thienyl or piperidinyl.
- the heterocyclyl group may contain up to 5, more preferably 1, 2 or 3 optional substituents.
- a substituent for a heterocyclyl group is selected from halogen, (C ⁇ _6)alkyl, aryl(Ci_6)alkyl, (C ⁇ _6)alkoxy, (C ⁇ _6)alkoxy(C ⁇ _6)alkyl, halo(C ⁇ .6)alkyl, hydroxy, amino, mono- and di-N-(C ⁇ _6)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C ⁇ _6)alkylcarbonyl, aryloxycarbonyl, (C ⁇ consecutive 5)alkoxycarbonyl(C ⁇ .6)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, l o aminosulphonyl, (C i _6)alkylthio, (C i _6)alkylsulphinyl, (
- R 2 When an adjacent pair of R 2 together with the carbon atoms to which they are attached form a carbocyclic or heterocyclic ring, it is preferably a 5- to 7-membered ring, which may be
- Heterocyclic rings preferably contain 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur; for example, pyrrole or pyrrolidine.
- a carbocyclic or heterocyclic ring formed by an adjacent pair of R ⁇ together with the carbon atoms to which they are attached may be optionally substituted on carbon or nitrogen by one or more substituents, e.g. up to 3 substituents. Examples of suitable substituents for the
- carbocyclic or heterocyclic ring include; halogen, (C ⁇ _g)alkyl, aryl(C ⁇ _6)alkyl, (C ⁇ . g)alkoxy, (C ⁇ _6)alkoxy(C;._6)alkyl, halo(C _6)alkyl, hydroxy, amino, mono- and di-N- (C ⁇ _6)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C ⁇ _6)alkylcarbonyl, aryloxycarbonyl, (C ⁇ _6)alkoxycarbonyl(C ⁇ _6-)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (C ⁇ _6)alkylthio,
- R as hydrogen, benzyl, methyl, ethyl, wo-propyl or t-butyl
- R 2 as hydrogen, methyl, ethyl, «-butyl, wo-propyl, t-butyl, phenyl, benzyl,
- R! is hydrogen or methyl
- R2 is hydrogen, methoxy, ethoxy, bromo, chloro, nitro, trifluoromethyi, or trifluoromethoxy.
- Examples of compounds of formula (I) are: N-(6-methyl-5 ,6,7,8-tetrahydro[ 1 ,6]naphthyridin-3 -yl)-N'-(3 -trifluoromethylphenyl)urea N-(6-memyl-5,6,7,8-te1rahydro[l,6]naphmyridine-3-yl)-N'-(4-trifluoromethoxyphenyl)urea N-(6-me yl-5,6,7,8-tefrahydro[l,6]naphthyridine-3-yl)-N'-(3-nitrophenyl)urea N-(6-methyl-5,6,7,8-tetrahydro[l,6]naphthyridine-3-yl)-N'-(3-methoxyphenyl)urea N-(6-methyl-5,6,7,8-tetrahydro[l,
- these compounds When synthesised, these compounds may be obtained in salt form, such as the hydrochloride or trifluoroacetate, and such salts also form part of this invention. Such salts may be used in preparing pharmaceutically acceptable salts.
- the compounds and their salts may be obtained as solvates, such as hydrates, and these also form part of this invention.
- the compounds of this invention possess anti-convulsant activity and are therefore believed to be useful for adminstration to mammals in the treatment and/or prevention of the disorders mentioned above, especially for humans, but also as a veterinary treatment.
- the administration of such compounds to a mammal may be by way of oral, parenteral, sub-lingual, nasal, rectal, topical or transdermal administration.
- a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound.
- Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg day, for example 1 to 6 mg kg day.
- the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, including sub-lingual, nasal, rectal, topical or parenteral (especially intravenous) composition.
- compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
- Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
- Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
- the tablets may be coated according to well known methods in the art.
- Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
- Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
- Suitable lubricants include, for example, magnesium stearate.
- Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
- solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl >-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate,
- Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
- fluid unit dose forms are prepared containing the compound and a sterile vehicle.
- the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
- Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
- compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
- the present invention provides a pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
- epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive
- Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (.ALS), which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
- MS multiple sclerosis
- ALS amyotrophic lateral sclerosis
- the present invention also provides a method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post- traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with JAIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
- Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS), comprising ad-rninistering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
- MS multiple sclerosis
- ALS amyotrophic lateral sclerosis
- the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
- epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other
- Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
- MS multiple sclerosis
- ALS amyotrophic lateral sclerosis
- the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
- Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (JALS).
- MS multiple sclerosis
- JALS amyotrophic lateral sclerosis
- Another aspect of the invention provides a process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (II)
- P is NH 2 or NCX, X being as defined for formula (I), with a compound of formula (III)
- Q is NCX or NH 2 and different from P, X being as defined for formula (I), and R-2A i s R ⁇ defined for formula (I) or a group or groups convertible to Rz, and where required converting a R ⁇ or R ⁇ A group to a R* or R 2 group, converting one R or R2 group to another R ⁇ or R 2 group, converting a salt product to the free base or another pharmaceutically acceptable salt, or converting a free base product to a pharmaceutically acceptable salt.
- Conventional conditions for condensation of isocyanates or isothiocyanates with amines may be used, for example treatment in an inert solvent such as toluene, DMF or dichloromethane at ambient or elevated temperature.
- Conversions of an R 1A or R 2A group to a R 1 or R 2 group typically arise when a protecting group is needed during the above coupling reaction or during the preparation of the reactants by the procedures described below.
- Interconversion of one R 1 or R 2 group to another typically arises when one compound of formula (I) is used as the immediate precursor of another compound of formula (I), or when it is easier to introduce a more complex or reactive substituent at the end of a synthetic sequence.
- Compounds of formula (VI) may be converted to compounds of formula (II) by hydro enation or reduction of the nitro group.
- a compound of formula (VI) may be hydrogenated by treatment with hydrogen in a suitable solvent such as methanol in the presence of a palladium/carbon catalyst.
- a compound of formula (NI) may be reduced with stannous chloride in concentrated hydrochloric acid in a suitable . solvent such as ethanol.
- the compounds of the present invention may contain a chiral centre, and therefore the above processes may produce a mixture of diastereoisomers.
- a single diastereoisomer may be prepared by separating such a mixture of diastereoisomers which has been synthesised using a racemic starting material, or by synthesis using an optically pure starting material.
- the compounds of this invention may be in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated.
- solvent of crystallisation may be present in the crystalline product.
- some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be present in the crystalline product. Crystallisation procedures will usually produce stoichiometric hydrates. Compounds containing variable amounts of water may be produced by processes such as lyophilisation.
- the compounds according to the invention are suitably provided in substantially pure form, for example at least 50% pure, suitable at least 60% pure, advantageously at least 75% pure, preferably at least 85% pure, more preferably at least 95% pure, especially at least 98% pure, all percentages being calculated as weight/weight.
- An impure or less pure form of a compound according to the invention may, for example, be used in the preparation of a more pure form of the same compound or of a related compound (for example a corresponding derivative) suitable for pharmaceutical use.
- the present invention also includes pharmaceutically acceptable salts and derivatives of the compounds of the invention.
- Salt formation may be possible when one of the substituents carries an acidic or basic group.
- Salts may be prepared by salt exchange in conventional manner.
- Acid-addition salts may be pharmaceutically acceptable or non-pharmaceutically acceptable. In the latter case, such salts may be useful for isolation and purification of the compound of the invention, or intermediates thereto, and will subsequently be converted into a pharmaceutically acceptable salt or the free base.
- 6-Benzyl-3-nitro-5,6,7,8-tetrahydro[l ,6]naphthyridine (790mg; 2.93 mmol) was dissolved in ethanol (100ml), the solution heated at 50°C and treated with a solution of stannous chloride dihydrate (2.65g; 11.73 mmol) in cone, hydrochloric acid (10ml). . fter 10 min, the reaction mixture was concentrated under reduced pressure, neutralised by addition of 2M aqueous sodium hydroxide and extracted with DCM. The extracts were combined, washed with water, saturated brine, dried (MgSO 4 ) and evaporated to dryness in vacuo. The brown residue was dissolved in methanol and SiO 2 added.
- 6-Methyl-3-nitro-5,6,7,8-tetrahydro[l,6]naphthyridine (2.72g, 1.41 mmol) was dissolved in methanol ( 100ml) and treated with 10% palladium on carbon (l.Og). The mixture was hydrogenated for 2h. The catalyst was removed by filtration through Celite, the filter bed washed with methanol and the filtrate evaporated to dryness under reduced pressure to give a yellow solid, which was triturated under diethyl ether and the solids collected by filtration, washed with diethyl ether and dried in vacuo (1.89g, 83%)
- the title compond was prepared in 74% yield from amine of Description 4 and phenyl isocyanate using a method similar to that of Example 1.
- WO 92/22293 discloses compounds having anti-convulsant activity, including inter alia the compound tr -(+)-6-acetyl-4S-(4-fluorobenzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-l-benzopyran-3R-ol (hereinafter referred to as Compound A). It has been found that the compounds of WO 92/22293 bind to a novel receptor obtainable from rat forebrain tissue, as described in WO 96/18650 (SrnithKline Beecham). The affinity of test compounds to the novel receptor site is assessed as follows.
- Whole forebrain tissue is obtained from rats.
- the tissue is first homogenised in buffer (usually 50mM Tris/HCl, pH 7.4).
- the homogenised tissue is washed by centrifugation and resuspension in the same buffer, then stored at -70°C until used.
- the affinity of the binding of test compounds to the novel site can be estimated by incubating together [3H]-Compound A and tissue in the presence of a range of concentrations cf the compound to be tested.
- the decrease in the level of specific [3H]- Compound A binding as a result of competition by increasing concentrations of the compound under test is plotted graphically, and non-linear regression analysis of the resultant curve is used to provide an estimate of compound affinity in terms of pKi value.
- the maximal electroshock seizure (MEST) threshold test in rodents is particularly sensitive for detecting potential anticonvulsant properties 1.
- anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.
- mice (naive male, Charles River, U.K. CD-I strain, 25 - 30g) are randomly assigned to groups of 10 - 20 and dosed orally or intraperitoneally at a dose volume of 10 ml/kg with various doses of compound (0.3 - 300 mg/kg) or vehicle. Mice are then subjected at 30 or 60 min post dose to a single electroshock (0.1 sec, 50Hz, sine wave form) adrninistered via corneal electrodes. The mean current and standard error required to induce a tonic seizure in 50% (CC5 Q ) of the mice in a particular treatment group is determined by the 'up and down' method of Dixon and Mood (1948)2. Statistical comparisons between vehicle- and drug-treated groups are made using the method of Litchfield and Wilcoxon (1949)3.
- the CC50 In control animals the CC50 is usually 14 - 18 mA. Hence the first animal in the control group is subjected to a current of 16 mA. If a tonic seizure does not ensue, the current is increased for a subsequent mouse. If a tonic convulsion does occur, then the current is decreased, and so on until all the animals in the group have been tested.
- the percentage increase or decrease in CC5 Q for each group compared to the control is calculated.
- Drugs are suspended in 1% methyl cellulose.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9720052.1A GB9720052D0 (en) | 1997-09-19 | 1997-09-19 | Novel compounds |
GB9720052 | 1997-09-19 | ||
PCT/EP1998/005904 WO1999015526A2 (en) | 1997-09-19 | 1998-09-15 | N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1017694A2 true EP1017694A2 (en) | 2000-07-12 |
Family
ID=10819406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98951421A Withdrawn EP1017694A2 (en) | 1997-09-19 | 1998-09-15 | N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1017694A2 (ja) |
JP (1) | JP2001517668A (ja) |
CA (1) | CA2303994A1 (ja) |
GB (1) | GB9720052D0 (ja) |
WO (1) | WO1999015526A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2425625A1 (en) * | 2000-10-12 | 2002-07-18 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
ES2287170T3 (es) | 2000-10-12 | 2007-12-16 | MERCK & CO., INC. | Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa. |
WO2002030930A2 (en) | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
JP2005504807A (ja) | 2001-09-26 | 2005-02-17 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 抗糖尿病薬としての1,8−ナフチリジン誘導体 |
WO2003077850A2 (en) | 2002-03-15 | 2003-09-25 | Merck & Co., Inc. | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
US8629276B2 (en) * | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
EP3097101B1 (en) | 2014-01-24 | 2020-12-23 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives as mgat2 inhibitors |
JP6972384B2 (ja) * | 2018-11-28 | 2021-11-24 | 武田薬品工業株式会社 | 複素環化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1302662B (ja) * | 1971-02-04 | |||
GB1574019A (en) * | 1977-01-14 | 1980-09-03 | Joullie International Sa | Therapeutically useful 3,4,5-trimethoxybenzene derivatives |
US4542144A (en) * | 1981-11-16 | 1985-09-17 | Mcneilab Inc. | Anticonvulsant N-aryl-N'-(2-thiazolidinylidene)ureas |
PT77429B (fr) * | 1982-10-05 | 1986-02-27 | Cortial | Procede pour preparer de nouvelles n-(amino-methyl-5 oxazolin-2 yl-2)n'-phenylurees et de compositions les contenant |
US5378848A (en) * | 1992-02-12 | 1995-01-03 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
DK41193D0 (da) * | 1993-04-07 | 1993-04-07 | Neurosearch As | Ionkanalaabnere |
GB9511355D0 (en) * | 1995-06-06 | 1995-08-02 | Fujisawa Pharmaceutical Co | Urea derivatives |
-
1997
- 1997-09-19 GB GBGB9720052.1A patent/GB9720052D0/en not_active Ceased
-
1998
- 1998-09-15 EP EP98951421A patent/EP1017694A2/en not_active Withdrawn
- 1998-09-15 CA CA002303994A patent/CA2303994A1/en not_active Abandoned
- 1998-09-15 WO PCT/EP1998/005904 patent/WO1999015526A2/en not_active Application Discontinuation
- 1998-09-15 JP JP2000512831A patent/JP2001517668A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9915526A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999015526A2 (en) | 1999-04-01 |
JP2001517668A (ja) | 2001-10-09 |
GB9720052D0 (en) | 1997-11-19 |
WO1999015526A3 (en) | 1999-05-20 |
CA2303994A1 (en) | 1999-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007507547A (ja) | キナーゼ阻害剤としての1,7−二置換アザベンゾイミダゾールの調製 | |
EP0805812A1 (en) | Bicyclic substituted hexahydrobenz(e)isoindole alpha-1- adrenergic antagonists | |
WO2004043960A1 (en) | 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof | |
WO2000007993A1 (en) | Substituted isoquinoleines and their use as anticonvulsivants | |
EP1178048A1 (en) | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | |
WO1999015526A2 (en) | N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives | |
AU678435B2 (en) | Substituted pyrroles | |
EP0861250B1 (en) | Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase | |
NZ250679A (en) | 2-phenyl-9h-imidazo[1,2-a] benzimidazole-3-acetamide derivatives; their preparation and pharmaceutical compositions | |
US6245778B1 (en) | 1,6-naphthyridine anti-convulsants | |
EP1053235A1 (en) | Oxazole derivatives as serotonin-1a receptor agonists | |
JP2001523678A (ja) | イソキノリン誘導体およびその治療用途 | |
US5929085A (en) | Amidine and isothiourea derivatives, compositions containing them and their use as inhibitors of nitric oxide synthase | |
AU750470B2 (en) | Tetrahydronaphthyridinyl-carboxamides having anti- convulsant activity | |
EP1005459A1 (en) | Substituted isoquinolines as anticonvulsivants | |
JP2002522436A (ja) | 三環式カルボキシアミド類 | |
AU2004235971B2 (en) | Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof | |
PL119517B1 (en) | Process for preparing novel,condensed pyrimidine derivatives with nodal nitrogen atompirimidina s central'nym atomom azota | |
WO2000008022A1 (en) | Urea derivatives | |
US6140322A (en) | Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase | |
CA2286452A1 (en) | Pyrimido-isoquinoline compounds with anticonvulsive action | |
IL107371A (en) | Phenyl-imidazolidinone derivatives, their preparation and pharmaceutical compositions containing them | |
TWI402264B (zh) | 芳基甲基苯并喹唑啉酮m1受體之正向異位性調節劑 | |
WO2000008023A1 (en) | Condensed tricyclic piperidines having anti-convulsant activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000309 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE ES FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 20020214 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020625 |